Skip to content

Simultaneous TransPRK and Corneal Collagen Cross-Linking

A Prospective Trial of Simultaneous Combined Transepithelial Photorefractive Keratectomy and Corneal Collagen Cross-linking for Keratoconus

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02208089
Acronym
TransPRKCXL
Enrollment
55
Registered
2014-08-04
Start date
2014-08-31
Completion date
2017-07-31
Last updated
2019-02-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Keratoconus

Keywords

Keratoconus, Corneal collagen cross-linking, Photorefractive keratectomy

Brief summary

Young patients with keratoconus face two problems: disease progression and corneal shape irregularity leading to poor vision even in spectacles. Corneal collagen cross-linking (CXL) is a new treatment designed to halt disease progression in keratoconus. The aim is to stiffen the cornea thereby preventing further shape deterioration. Topography or wavefront guided transepithelial photorefractive keratectomy (transPRK) uses the excimer laser (the laser used to correct sight in 'laser eye surgery') to reduce corneal shape irregularity in early stage keratoconus, reducing dependence on contact lenses. In transPRK, the corneal skin layer is removed in a well controlled, no touch procedure, preparing the cornea for CXL. Performing both treatments simultaneously (combining both procedures in one operation) may offer several advantages over performing CXL first then waiting for corneal shape to stabilise before performing transPRK. In particular, visual rehabilitation may be faster. This study aims to evaluate visual recovery after simultaneous CXL and transPRK in progressive early stage keratoconus. Visual recovery in these patients will be compared with results for a similar group of patients with early stage keratoconus who have already been treated with CXL alone.

Detailed description

Features which distinguish this trial from previous trials of combined photorefractive keratectomy (PRK) and corneal collagen cross-linking (CXL) are: a rapid, pulsed light, CXL protocol; and a treatment programming algorithm for PRK designed to target higher order aberrations only with no compensatory additional laser corneal tissue removal. Excimer laser treatment will be performed with the Schwind Amaris 750S laser (www.eye-tech-solutions.com). Unique features of this system utilised here include: * Pre-programmed transepithelial ablation - laser removal of the minimum area of corneal epithelium required for PRK promoting more rapid recovery than conventional methods (20% alcohol application and manual epithelial removal). An 8mm diameter ablation zone will be applied throughout. * Enhanced algorithms for minimal laser tissue removal - in this trial, the investigators are targeting higher order aberrations only (coma in particular) with the aim of improving spectacle corrected visual acuity without regard to the predicted spherocylindrical outcome. Unlike other current excimer laser platforms, Schwind Amaris treatment programming software allows treatment for irregular astigmatism without additional compensatory laser tissue removal to correct the spherocylindrical change induced by treatment of higher order aberrations. Higher order aberrations can also be treated selectively. The investigators will use an algorithm step that targets only aberrations (up to 6th order Zernike polynomials) with a value greater than 2 standard deviations from the population mean in normative data. These treatment planning steps allow the laser to create a large diameter treatment with minimal treatment depth. Laser epithelial removal alone (transPTK at depth 55µm) removes a maximum 65µm of tissue in the corneal periphery. For patients with 390µm at the thinnest point, transPTK will therefore leave above 325µm residual stromal thickness prior to CXL. This is in line with recommendations for minimum stromal thickness after epithelial removal in the CXL protocol used here. Limited stromal reshaping is achieved in this simple embodiment of transPRK for keratoconus by taking advantage of the masking effect of the corneal epithelium, which tends to be thinnest over the cone apex. Where the thinnest point is greater than 390µm, further reductions in corneal shape irregularity can be produced by adding either wavefront or topography guided additional stromal ablation using custom programming on the Schwind Amaris laser. Ocular wavefront (aberrometry) guided smoothing will be used for patients with a 5.5mm or larger pupil at scanning and a consistent scan sequence (3 scans within 0.5 dioptre (D) spherical equivalent refraction). Corneal wavefront (topography) guided smoothing will be used for patients with ocular wavefront scans which do not meet these criteria. In all cases, a minimum corneal stromal thickness prior to CXL of 325µm will be preserved. Immediately after PRK, corneal collagen cross-linking will be performed using the following protocol Riboflavin soak: 10 minutes total soak time; application of 0.1% riboflavin preparation (VibeX Rapid - www.avedro.com) each 2 minutes with gentle balanced salt solution irrigation to remove excess riboflavin prior to UV light exposure. UV light exposure: Total treatment time 8 minutes (370nm wavelength; 30mW/cm2 irradiance; 4 minutes total UV exposure time, pulsed 1.5 seconds on 1.5 seconds off; Avedro KXL I light source) Mitomycin C will not be used. A bandage contact lens will be applied at the end of treatment and a standard post photorefractive keratectomy topical and systemic drug treatment regimen will be used in every case with initial clinical review 1 week after surgery.

Interventions

PROCEDURETransepithelial Photorefractive Keratectomy (TransPRK)

Aberrometry or topography guided transepithelial photorefractive keratectomy (TransPRK) using the Schwind Amaris 750s excimer laser (www.eye-tech-solutions.com), an 8mm treatment diameter, and a tissue saving algorithm targeting selected higher order aberrations only. TransPRK will be followed immediately by corneal collagen cross-linking (CXL).

Riboflavin soak: 10 minutes total soak time; application of 0.1% riboflavin preparation (VibeX Rapid - www.avedro.com) each 2 minutes with gentle balanced salt solution irrigation to remove excess riboflavin prior to UV light exposure. UV light exposure: Total treatment time 8 minutes (370nm wavelength; 30mW/cm2 irradiance; 4 minutes total UV exposure time, pulsed 1.5 seconds on 1.5 seconds off; Avedro KXL I light source)

Sponsors

Moorfields Eye Hospital NHS Foundation Trust
CollaboratorOTHER
Bruce Allan
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Interventional case series with matched historical controls

Eligibility

Sex/Gender
ALL
Age
18 Years to 35 Years
Healthy volunteers
No

Inclusion criteria

* Patients with progressive stage II or III keratoconus * CDVA \< 0.00 logMAR or subjective problems with spectacle corrected visual quality (ghost images or light scatter symptoms)

Exclusion criteria

* Active ocular surface disease * Minimum corneal thickness \<390µm (leaving 325µm residual stromal thickness after transPTK - in line with minimum thickness recommendations for the study CXL protocol) * Vulnerable groups (patients whose capacity for giving informed consent to participate in the trial may be impaired)

Design outcomes

Primary

MeasureTime frameDescription
Change in LogMAR Corrected Distance Visual Acuity (CDVA)Preoperative vs 24 monthsChange in spectacle corrected logarithm minimum angle of resolution (LogMAR) distance visual acuity recorded in a 4m testing lane in photopic lighting conditions between baseline measurement and final review at 24 months (note that negative change = better vision; 0.1 logMAR units = 1 line on the test chart)

Secondary

MeasureTime frameDescription
Clinically Significant Visual GainPreoperative vs 24 months postoperativeNumber of participants with gain of ≥2 lines (≥0.20 logMAR units) corrected distance visual acuity (CDVA) on a standard 5 letter per line EDTRS visual acuity testing chart
Clinically Significant Visual Losspreoperative vs 24 months postoperativeNumber of participants with loss of ≥2 lines (≥0.20 LogMAR units) corrected distance visual acuity (CDVA)
Change in Kmax - Maximum Local Anterior Corneal Surface Curvature on Tomography MapPreoperative vs 24 months postoperativePentacam (www.oculus.de) measure: Maximum local curvature (Kmax). Reduction in dioptric value = corneal flattening
Progression Rate6 months postoperative - 24 months postoperativeThe number of participants with possible keratoconus disease progression after treatment defined by a ≥1.5D increase in Kmax, anterior and posterior K2 (maximum local corneal curvature, maximum anterior and posterior meridional corneal curvature) measured using a Pentacam HD corneal tomographer (www.oculus.de).

Countries

United Kingdom

Participant flow

Recruitment details

Patients with Stage I-III keratoconus and corrected vision \<20/20 were recruited. Recruitment period: August 2014-July2015. Location: dedicated keratoconus clinic at Moorfields Eye Hospital, London.

Pre-assignment details

63 eligible patients were screened; 11 declined to participate after discussing consent information; 5 patients were found to be ineligible because of insufficient residual corneal stromal depth following PRK programming, leaving 47 patients who were treated with TransPRK/CXL

Participants by arm

ArmCount
TransPRKCXL
Simultaneous combined transepithelial photorefractive keratectomy (TransPRK) and corneal collagen cross-linking (CXL) Transepithelial Photorefractive Keratectomy (TransPRK): Aberrometry or topography guided transepithelial photorefractive keratectomy (TransPRK) using the Schwind Amaris 750s excimer laser (www.eye-tech-solutions.com), an 8mm treatment diameter, and a tissue saving algorithm targeting selected higher order aberrations only. TransPRK will be followed immediately by corneal collagen cross-linking (CXL). Corneal Collagen Cross-Linking (CXL): Riboflavin soak: 10 minutes total soak time; application of 0.1% riboflavin preparation (VibeX Rapid - www.avedro.com) each 2 minutes with gentle balanced salt solution irrigation to remove excess riboflavin prior to UV light exposure. UV light exposure: Total treatment time 8 minutes (370nm wavelength; 30mW/cm2 irradiance; 4 minutes total UV exposure time, pulsed 1.5 seconds on 1.5 seconds off; Avedro KXL I light source)
47
CXL Only
Corneal collagen cross-linking (CXL), manual corneal epithelial removal, no excimer laser treatment CXL protocol was identical in both study arms. After corneal epithelial removal, a 10 minute soak with Vibex rapid (www.avedro.com) was followed by 8 minutes pulsed UV light using a uniform beam source (KXL - www.avedro.com) and a 1.5 second on/off cycle (7.2mJ/cm2 total energy @ 30mW/cm2 irradiance).
47
Total94

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyLost to Follow-up60
Overall StudyWithdrawal by Subject10

Baseline characteristics

CharacteristicTransPRKCXLCXL OnlyTotal
Age, Continuous24.6 years
STANDARD_DEVIATION 3.8
24.3 years
STANDARD_DEVIATION 4.3
24.5 years
STANDARD_DEVIATION 4.1
Region of Enrollment
United Kingdom
47 participants47 participants94 participants
Sex: Female, Male
Female
14 Participants16 Participants30 Participants
Sex: Female, Male
Male
33 Participants31 Participants64 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 470 / 47
other
Total, other adverse events
1 / 470 / 47
serious
Total, serious adverse events
0 / 470 / 47

Outcome results

Primary

Change in LogMAR Corrected Distance Visual Acuity (CDVA)

Change in spectacle corrected logarithm minimum angle of resolution (LogMAR) distance visual acuity recorded in a 4m testing lane in photopic lighting conditions between baseline measurement and final review at 24 months (note that negative change = better vision; 0.1 logMAR units = 1 line on the test chart)

Time frame: Preoperative vs 24 months

ArmMeasureValue (MEAN)Dispersion
TransPRKCXLChange in LogMAR Corrected Distance Visual Acuity (CDVA)-0.13 LogMAR CDVAStandard Deviation 0.2
CXL OnlyChange in LogMAR Corrected Distance Visual Acuity (CDVA)-0.05 LogMAR CDVAStandard Deviation 0.13
Comparison: Null hypothesis = TransPRK produced no gains in vision over and above those produced by CXL onlyp-value: 0.03t-test, 2 sided
Secondary

Change in Kmax - Maximum Local Anterior Corneal Surface Curvature on Tomography Map

Pentacam (www.oculus.de) measure: Maximum local curvature (Kmax). Reduction in dioptric value = corneal flattening

Time frame: Preoperative vs 24 months postoperative

ArmMeasureValue (MEAN)Dispersion
TransPRKCXLChange in Kmax - Maximum Local Anterior Corneal Surface Curvature on Tomography Map-5.5 DioptresStandard Deviation 2.6
CXL OnlyChange in Kmax - Maximum Local Anterior Corneal Surface Curvature on Tomography Map-0.54 DioptresStandard Deviation 1.6
Secondary

Clinically Significant Visual Gain

Number of participants with gain of ≥2 lines (≥0.20 logMAR units) corrected distance visual acuity (CDVA) on a standard 5 letter per line EDTRS visual acuity testing chart

Time frame: Preoperative vs 24 months postoperative

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
TransPRKCXLClinically Significant Visual Gain12 Participants
CXL OnlyClinically Significant Visual Gain3 Participants
Comparison: Null hypothesis = an equal proportion of patients in both study arms have clinically significant visual gainsp-value: 0.005Chi-squared
Secondary

Clinically Significant Visual Loss

Number of participants with loss of ≥2 lines (≥0.20 LogMAR units) corrected distance visual acuity (CDVA)

Time frame: preoperative vs 24 months postoperative

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
TransPRKCXLClinically Significant Visual Loss1 Participants
CXL OnlyClinically Significant Visual Loss2 Participants
Comparison: null hypothesis = rates of clinically significant visual loss are equal for TransPRKCXL and CXL onlyp-value: 0.13Chi-squared
Secondary

Progression Rate

The number of participants with possible keratoconus disease progression after treatment defined by a ≥1.5D increase in Kmax, anterior and posterior K2 (maximum local corneal curvature, maximum anterior and posterior meridional corneal curvature) measured using a Pentacam HD corneal tomographer (www.oculus.de).

Time frame: 6 months postoperative - 24 months postoperative

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
TransPRKCXLProgression Rate3 Participants
CXL OnlyProgression Rate3 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026